<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">62019</article-id><article-id pub-id-type="doi">10.7554/eLife.62019</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title><italic>In vitro </italic>proteasome processing of neo-splicetopes does not predict their presentation <italic>in vivo</italic></article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-202019"><name><surname>Willimsky</surname><given-names>Gerald</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9693-948X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-205473"><name><surname>Beier</surname><given-names>Christin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-205474"><name><surname>Immisch</surname><given-names>Lena</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-231131"><name><surname>Papafotiou</surname><given-names>Georgios</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-205475"><name><surname>Scheuplein</surname><given-names>Vivian</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-205476"><name><surname>Goede</surname><given-names>Andrean</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9044-9869</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-205477"><name><surname>Holzhütter</surname><given-names>Hermann-Georg</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-151802"><name><surname>Blankenstein</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-32103"><name><surname>Kloetzel</surname><given-names>Peter M</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Experimental and Translational Cancer Immunology</institution>, <institution>Institute of Immunology (Charité - Universitätsmedizin Berlin) and German Cancer Research Center (DKFZ Heidelberg)</institution>, <addr-line><named-content content-type="city">Berlin</named-content></addr-line>, <country>Germany</country></aff><aff id="aff2"><institution content-type="dept">Biochemistry</institution>, <institution>Institute of Biochemistry (Charité - Universitätsmedizin Berlin)</institution>, <addr-line><named-content content-type="city">Berlin</named-content></addr-line>, <country>Germany</country></aff><aff id="aff3"><institution content-type="dept">Molecular Immunology</institution>, <institution>Max-Delbrück Center for Molecular Medicine</institution>, <addr-line><named-content content-type="city">Berlin</named-content></addr-line>, <country>Germany</country></aff><aff id="aff4"><institution content-type="dept">Physiologie (</institution>, <institution>Institut für Physiologie (Charité - Universitätsmedizin Berlin)</institution>, <addr-line><named-content content-type="city">Berlin</named-content></addr-line>, <country>Germany</country></aff><aff id="aff5"><institution>Max Delbrück Center for Molecular Medicine in Helmholtz Association</institution>, <addr-line><named-content content-type="city">Berlin</named-content></addr-line>, <country>Germany</country></aff><aff id="aff6"><institution content-type="dept">Institut für Biochemie</institution>, <institution>Charité - Universitätsmedizin Berlin</institution>, <addr-line><named-content content-type="city">Berlin</named-content></addr-line>, <country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-154970"><name><surname>Cerullo</surname><given-names>Vincenzo</given-names></name><role>Reviewing editor</role><aff><institution>University of Helsinki</institution>, <country>Finland</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>gerald.willimsky@charite.de</email> (GW);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>p-m.kloetzel@charite.de</email> (PK);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>20</day><month>04</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e62019</elocation-id><history><date date-type="received"><day>11</day><month>08</month><year>2020</year></date><date date-type="accepted"><day>15</day><month>04</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Willimsky et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Willimsky et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-62019-v2.pdf"/><abstract><p>Proteasome catalyzed peptide splicing (PCPS) of cancer-driving antigens could generate attractive neoepitopes to be targeted by TCR-based adoptive T cell therapy. Based on a spliced peptide prediction algorithm TCRs were generated against putative KRAS<sup>G12V</sup> and RAC2<sup>P29L</sup> derived neo-splicetopes with high HLA-A*02:01 binding affinity. TCRs generated in mice with a diverse human TCR repertoire specifically recognized the respective target peptides with high efficacy. However, we failed to detect any neo-splicetope specific T cell response when testing the <italic>in vivo</italic> neo-splicetope generation and obtained no experimental evidence that the putative KRAS<sup>G12V</sup>- and RAC2<sup>P29L</sup>-derived neo-splicetopes were naturally processed and presented. Furthermore, only the putative RAC2<sup>P29L</sup>-derived neo-splicetopes was generated by <italic>in vitro</italic> PCPS. The experiments pose severe questions on the notion that available algorithms or the <italic>in vitro </italic>PCPS reaction reliably simulate <italic>in vivo</italic> splicing and argue against the general applicability of an algorithm-driven 'reverse immunology' pipeline for the identification of cancer-specific neo-splicetopes.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>SFB-TR36</award-id><principal-award-recipient><name><surname>Willimsky</surname><given-names>Gerald</given-names></name><name><surname>Blankenstein</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005972</institution-id><institution>Deutsche Krebshilfe</institution></institution-wrap></funding-source><award-id>111546</award-id><principal-award-recipient><name><surname>Willimsky</surname><given-names>Gerald</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100017268</institution-id><institution>Berlin Institute of Health</institution></institution-wrap></funding-source><award-id>CRG-1</award-id><principal-award-recipient><name><surname>Blankenstein</surname><given-names>Thomas</given-names></name><name><surname>Kloetzel</surname><given-names>Peter M</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>DKTK joint funding</institution></institution-wrap></funding-source><award-id>NEO-ATT</award-id><principal-award-recipient><name><surname>Willimsky</surname><given-names>Gerald</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution>Berliner Krebsgesellschaft</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Kloetzel</surname><given-names>Peter M</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>Helmholtz-Gemeinschaft, Zukunftsthema 'Immunology and Inflammation'</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Willimsky</surname><given-names>Gerald</given-names></name><name><surname>Blankenstein</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal experiments were performed according to institutional and national guidelines and regulations. The experiments were approved by the governmental authority (Landesamt für Gesundheit und Soziales, Berlin, H0086/16).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Additional source data comprising databases for ProteomDiscoverer, Kras/RAC2 kinetics, cleavage maps and PD2.1 result files have been submitted to Dryad under DOI:10.5061/dryad.jq2bvq88b</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>G Willimsky</collab><collab>C Beier</collab><collab>L Immisch</collab><collab>V Scheuplein</collab><collab>A Goede</collab><collab>HG Holzhütter</collab><collab>T Blankenstein</collab><collab>PM Kloetzel</collab></person-group><year iso-8601-date="2021">2021</year><source>Willimsky_et_al_11-08-2020-RA-eLife-62019_Supplementary data files</source><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.5061/dryad.jq2bvq88b">http://dx.doi.org/10.5061/dryad.jq2bvq88b</ext-link><comment>Dryad Digital Repository, doi:10.5061/dryad.jq2bvq88b</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-62019-supp-v2.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>